Ruxolitinib in Estrogen Receptor Positive Breast Cancer
Status:
Completed
Trial end date:
2016-04-09
Target enrollment:
Participant gender:
Summary
This is a Phase II investigator-Initiated trial of the Investigational Drug, Ruxolitinib, in
combination with Exemestane in patients with estrogen-receptor positive advanced breast
cancer. The objective of this study is to determine the preliminary safety and efficacy of
the combination of exemestane and Ruxolitinib (INCB018424).
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania